Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

9.17

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

0.05

EPS Last/This Y

-0.05

EPS This/Next Y

0.06

Price

3.27

Target Price

5.25

Analyst Recom

1.5

Performance Q

-9.42

Relative Volume

0.71

Beta

0.86

Ticker: ABUS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04ABUS3.240.310.0022193
2025-07-07ABUS3.140.310.0022271
2025-07-08ABUS3.180.310.0222285
2025-07-09ABUS3.330.310.0022302
2025-07-10ABUS3.270.302.8022554
2025-07-11ABUS3.180.300.0022571
2025-07-14ABUS3.240.300.1622682
2025-07-15ABUS3.120.300.0322821
2025-07-16ABUS3.110.300.0022887
2025-07-17ABUS3.130.300.0422947
2025-07-18ABUS3.120.300.0022971
2025-07-21ABUS3.130.310.3422191
2025-07-22ABUS3.160.310.0022220
2025-07-23ABUS3.220.310.0022252
2025-07-24ABUS3.240.190.0032270
2025-07-25ABUS3.210.190.0032280
2025-07-28ABUS3.350.190.0032282
2025-07-29ABUS3.310.190.0032287
2025-07-30ABUS3.310.190.0032297
2025-07-31ABUS3.270.190.0032378
2025-08-01ABUS3.270.190.0032616
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04ABUS3.2440.6- -0.43
2025-07-07ABUS3.1440.6- -0.43
2025-07-08ABUS3.1840.6- -0.43
2025-07-09ABUS3.3440.6- -0.43
2025-07-10ABUS3.2840.6- -0.43
2025-07-11ABUS3.1740.6- -0.43
2025-07-14ABUS3.2440.6- -0.43
2025-07-15ABUS3.1340.6- -0.43
2025-07-16ABUS3.1140.6- -0.43
2025-07-17ABUS3.1440.6- -0.43
2025-07-18ABUS3.1240.6- -0.43
2025-07-21ABUS3.1440.6- -0.43
2025-07-22ABUS3.1540.6- -0.43
2025-07-23ABUS3.2340.6- -0.43
2025-07-24ABUS3.2440.6- -0.43
2025-07-25ABUS3.2240.6- -0.43
2025-07-28ABUS3.3540.6- -0.43
2025-07-29ABUS3.3040.6- -0.43
2025-07-30ABUS3.3040.6- -0.43
2025-07-31ABUS3.2840.6- -0.43
2025-08-01ABUS3.2740.6- -0.43
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04ABUS-0.189.238.64
2025-07-07ABUS-0.189.218.64
2025-07-08ABUS-0.189.218.64
2025-07-09ABUS-0.189.218.64
2025-07-10ABUS-0.189.218.64
2025-07-11ABUS-0.189.219.26
2025-07-14ABUS-0.189.419.26
2025-07-15ABUS-0.189.419.26
2025-07-16ABUS-0.189.419.26
2025-07-17ABUS-0.189.419.26
2025-07-18ABUS-0.189.419.26
2025-07-21ABUS-0.189.479.26
2025-07-22ABUS-0.189.479.26
2025-07-23ABUS-0.189.479.26
2025-07-24ABUS-0.189.479.26
2025-07-25ABUS-0.189.479.17
2025-07-28ABUS-0.189.339.17
2025-07-29ABUS-0.189.339.17
2025-07-30ABUS-0.189.339.17
2025-07-31ABUS-0.189.339.17
2025-08-01ABUS-0.189.339.17
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.09

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

-0.18

Institutional Transactions

9.33

Beta

0.86

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

24

Growth Score

24

Sentiment Score

60

Actual DrawDown %

49.7

Max Drawdown 5-Year %

-66

Target Price

5.25

P/E

Forward P/E

PEG

P/S

97.86

P/B

7.91

P/Free Cash Flow

EPS

-0.4

Average EPS Est. Cur. Y​

-0.43

EPS Next Y. (Est.)

-0.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1195.86

Relative Volume

0.71

Return on Equity vs Sector %

-120.5

Return on Equity vs Industry %

-101.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Arbutus Biopharma Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 44
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today
news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance
stock history ABUS – Arbutus Biopharma Corporation invest stock market
stock prices ABUS premarket after hours
ticker ABUS fair value insiders trading